Study on whether Anagrelide accelerates myelofibrosis

Anagrelide is considered an effective drug in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders by inhibiting platelet production to control the patient's platelet count. However, long-term use of anagrelide may be associated with potential side effects, one of which is the risk of myelofibrosis.

Myelofibrosis is a disease caused by the excessive proliferation of fibrous tissue in the bone marrow, often accompanied by a gradual decline in bone marrow function. In some patients, long-term use of anagrelide may lead to the proliferation of bone marrow cells and fibrous tissue, thereby exacerbating the progression of myelofibrosis. Studies have shown that anagrelide may affect the bone marrow microenvironment, interfere with normal hematopoietic function, lead to abnormal proliferation of bone marrow fibrous tissue, and may ultimately aggravate myelofibrosis.

Currently, there are some studies on the association between anagrelide and myelofibrosis, but the results are not entirely consistent. Some clinical reports indicate that long-term use of anagrelide may lead to the development of myelofibrosis, especially in patients with pre-existing myeloproliferative disorders. By inhibiting platelet production, anagrelide may affect the growth and development of other cells in the bone marrow, causing an overall imbalance in the blood system. In addition, the antiplatelet effect of anagrelide may also affect the production of other blood cells in the bone marrow, thereby promoting the proliferation of fibrous tissue.

However, other studies suggest that while anagrelide may be associated with the development of myelofibrosis in some cases, this risk is not universal, especially with appropriate monitoring. Many patients are able to control thrombocytosis without developing serious myelofibrosis problems using anagrelide.

Reference materials:https://go.drugbank.com/drugs/DB00261